In its conference call discussing the acquisition, Agilent stated that the purchase will add sales growth via entry into the fast-growing anatomic pathology and molecular diagnostic markets, increase its percentage of recurring revenues from 25% to 30% and allow Agilent to grow Dako’s business in emerging markets. Revenue synergies are estimated to total $30 million. The acquisition is projected to add $0.35 to non-GAPP fiscal 2013 EPS and to be immediately accretive. Agilent plans to invest $10 million into the business this year. Dako is distributing Agilent’s new SureFISH (fluorescent in situ hybridization) probes (see IBO 4/30/12), along with its own buffer, into the anatomic pathology market. Agilent expects revenue synergies of $39 million in fiscal 2013. Dako is expected to record $373 million in sales this year, with a $68 million operating profit and 18% operating margin. Pathology accounts for 85% of Dako sales, consisting primarily of sales of immunohistochemistry and in situ hybridization products. The purchase also makes use of Agilent’s offshore cash.